Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 9/20 | 0.56 |
| ▸ | SRC | P12931 | 6/20 | 0.56 |
| ▸ | CDK8 | P49336 | 2/20 | 0.54 |
| ▸ | CDK1 | P06493 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | BRAF | P15056 | 2/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.49 |
| ▸ | CCNC | P24863 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
| ▸ | TEK | Q02763 | 1/20 | 0.48 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.48 |
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | ABL2 | P42684 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22684847 | 1.00 | ABL1 (0.56) | ABL1SRCCDK8CDK1CDK2 | |
| SCHEMBL22684880 | 0.93 | ABL1 (0.47) | ABL1SRCCDK8CDK1CDK2 | |
| SCHEMBL29629248 | 0.93 | ABL1 (0.47) | ABL1SRCCDK8CDK1CDK2 | |
| SCHEMBL23068646 | 0.90 | CDK8 (0.59) | ABL1SRCCDK8CDK1CDK2 | |
| SCHEMBL29629218 | 0.90 | CDK8 (0.59) | ABL1SRCCDK8CDK1CDK2 | |
| SCHEMBL22684853 | 0.89 | CDK8 (0.54) | ABL1SRCCDK8CDK1CDK2 | |
| SCHEMBL29629216 | 0.89 | CDK8 (0.54) | ABL1SRCCDK8CDK1CDK2 | |
| SCHEMBL29629225 | 0.89 | CDK8 (0.54) | ABL1SRCCDK8CDK1CDK2 | |
| SCHEMBL23068668 | 0.89 | CDK8 (0.54) | ABL1SRCCDK8CDK1CDK2 | |
| SCHEMBL23068639 | 0.88 | EGFR (0.54) | ABL1SRCCDK8CDK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111757881-B | 5- (Pyrimidin-4-yl) thiazol-2-yl urea derivatives as therapeutic agents | 澳升医药公司 | 2024-05-07 | — | — | CN | claimed |
| EP-3740484-B1 | 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2024-09-11 | — | — | EP | disclosed |
| CN-111757881-B | 5- (Pyrimidin-4-yl) thiazol-2-yl urea derivatives as therapeutic agents | 澳升医药公司 | 2024-05-07 | — | — | CN | disclosed |
| US-20230092876-A1 | 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2023-03-23 | — | — | US | disclosed |
| US-11325900-B2 | 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents | AUCENTRA HOLDINGS PTY LTD (AU) | 2022-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230092876-A1 | 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS | CDK8, CDK18, CDK9 | ABL1 268/4885SRC 689/4885CDK8 1/4885 |
| US-11325900-B2 | 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents | CDK8, CDK18, CDK9 | ABL1 268/4885SRC 689/4885CDK8 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.